SOCS6 Antibody

What is SOCS6 and why is it significant in immunological research?

SOCS6 belongs to the cytokine-induced STAT inhibitor (CIS) family, also known as suppressor of cytokine signaling (SOCS) or STAT-induced STAT inhibitor (SSI) protein family. It contains a characteristic SH2 domain and a CIS homolog domain, functioning as a cytokine-inducible negative regulator of signaling pathways .

SOCS6 plays a crucial role in T cell activation through its interaction with p56lck, a T cell-specific tyrosine kinase essential for T cell receptor (TCR)-mediated signaling. SOCS6 specifically binds to the active form of p56lck and targets it for ubiquitination and subsequent proteasomal degradation, thereby negatively regulating T cell activation . This mechanism provides a complementary regulatory control to other established T cell regulation modes such as Csk kinase activity and CD45 dephosphorylation .

Beyond immune regulation, SOCS6 has been identified as a potential tumor suppressor, with biallelic inactivation of the SOCS6 gene frequently observed in human gastric cancer . This multifunctional role makes SOCS6 a significant target for immunological, cancer, and cell signaling research.

What are the primary applications of SOCS6 antibodies in research?

SOCS6 antibodies serve multiple experimental purposes in research settings:

• Immunohistochemistry (IHC): Detection of SOCS6 expression in tissue samples, particularly in cancer tissues including mammary, liver, and lung cancers, with recommended dilutions of 1:50-1:200

• Western Blotting: Examination of SOCS6 protein expression levels and post-translational modifications in cell and tissue lysates

• Co-immunoprecipitation: Investigation of protein-protein interactions involving SOCS6, particularly with p56lck, DRP1, and PGAM5

• Immunofluorescence Microscopy: Visualization of SOCS6 subcellular localization, especially its recruitment to the immunological synapse upon T cell activation

• Functional Assays: Monitoring SOCS6's role in ubiquitination, proteasomal targeting, and cell death pathways

These applications collectively enable researchers to understand the diverse roles of SOCS6 in cellular signaling, immune regulation, mitochondrial dynamics, and cancer biology.

What is the subcellular localization of SOCS6 and how can it be visualized?

SOCS6 exhibits dynamic subcellular localization patterns depending on cellular context and activation state:

• Cytosolic distribution in resting cells

• Plasma membrane association following cellular activation

• Immunological synapse localization during T cell-APC (antigen-presenting cell) conjugation

• Mitochondrial targeting during apoptotic processes

For visualization of SOCS6 localization:

When performing immunofluorescence studies, optimal fixation and permeabilization protocols are crucial as SOCS6 exhibits both cytosolic and membrane associations .

How does SOCS6 regulate T cell activation at the molecular level?

SOCS6 regulates T cell activation through a multistep process involving specific interactions with signaling components:

• Selective binding to activated p56lck: SOCS6 specifically interacts with p56lck(F505), which mimics the active form of p56lck, but not with wild type p56lck

• Time-dependent association: In Jurkat T cells, SOCS6 binding to p56lck is detected starting from 10 minutes after T cell activation, with maximum binding observed at 60-120 minutes

• Immunological synapse recruitment: Upon APC-T cell conjugation, SOCS6 is recruited to the immunological synapse where it colocalizes with active p56lck

• Promotion of ubiquitination: SOCS6 facilitates p56lck ubiquitination, targeting it for proteasomal degradation

• Suppression of downstream signaling: SOCS6 overexpression leads to repression of TCR-dependent interleukin-2 promoter activity

Importantly, SOCS6 specifically inhibits TCR-mediated activation but shows no inhibitory effect on T cell activation induced by PMA plus A23187 stimulation, indicating that SOCS6 negatively regulates TCR-proximal signaling events upstream of PMA/ionomycin pathways .

What protein-protein interactions are mediated by SOCS6 and how can antibodies help investigate these?

SOCS6 engages in multiple protein-protein interactions critical to its diverse cellular functions:

For optimal detection of these interactions:

• Use mild lysis conditions (e.g., 0.25% Nonidet P-40 in PBS) to preserve protein complexes

• Include proteasome inhibitors when studying interactions with proteins targeted for degradation

• For TCR-stimulated cells, examine timepoints between 60-120 minutes post-stimulation for optimal SOCS6-p56lck binding

• In primary T cells, SOCS6 expression increases approximately 1 hour after T cell activation, coinciding with increased p56lck ubiquitination

The transient nature of these interactions necessitates careful experimental design and timing considerations when using antibody-based detection methods.

What is the role of SOCS6 in mitochondrial dynamics and apoptosis?

SOCS6 plays a critical role in regulating mitochondrial dynamics and promoting apoptosis through several mechanisms:

• Mitochondrial targeting: SOCS6 can localize to mitochondria under specific cellular conditions

• Promotion of mitochondrial fragmentation: SOCS6 induces mitochondrial fragmentation mediated through increased DRP1 fission activity

• Complex formation with DRP1 and PGAM5: SOCS6 forms a complex with the mitochondrial fission protein DRP1 and the phosphatase PGAM5

• Regulation of DRP1 activity: SOCS6 attenuates DRP1 phosphorylation and promotes DRP1 mitochondrial translocation

• Facilitation of intrinsic apoptosis: SOCS6 promotes intrinsic apoptotic pathways, with increased Bax conformational change, mitochondrial targeting, and oligomerization

Research has demonstrated that SOCS6-mediated apoptosis is tightly coupled to its effects on mitochondrial dynamics, establishing a mechanistic link between these processes. Antibody-based detection methods can help visualize these interactions and track the mitochondrial recruitment of SOCS6 during apoptotic events .

What are the optimal conditions for using SOCS6 antibodies in co-immunoprecipitation studies?

Successful co-immunoprecipitation (Co-IP) of SOCS6 and its interaction partners requires careful optimization of experimental conditions:

For detecting interactions with p56lck, note that SOCS6 preferentially binds the active form (F505 mutant) rather than wild-type p56lck . This specificity should be considered when designing experimental controls.

When studying ubiquitination events mediated by SOCS6, consider including deubiquitinating enzyme inhibitors in your lysis buffer to preserve ubiquitin modifications.

How can researchers validate the specificity of SOCS6 antibodies?

Rigorous validation of SOCS6 antibody specificity is essential for reliable experimental results:

• Genetic approaches:

  • Use SOCS6 knockout/knockdown cells as negative controls

  • Test reactivity in cells overexpressing tagged SOCS6 as positive controls

  • Assess cross-reactivity with related SOCS family members (SOCS1-5, SOCS7, CIS)

• Analytical validation:

  • Confirm detection of protein at expected molecular weight (~59.5 kDa for human SOCS6)

  • Conduct peptide competition assays to block specific binding

  • Verify immunogen sequence alignment with target species (human, mouse)

• Application-specific validation:

  • For IHC: Compare staining patterns across validated tissue samples (e.g., human mammary, liver, and lung cancer tissues)

  • For immunofluorescence: Confirm subcellular localization matches known distribution patterns (cytosol, plasma membrane, immunological synapse)

• Multi-antibody approach:

  • Compare results using antibodies targeting different epitopes of SOCS6

  • Validate observations using both monoclonal and polyclonal antibodies when possible

The polyclonal SOCS6 antibody described in the search results was generated against recombinant fusion protein of human SOCS6 (NP_004223.2) and validated for IHC applications in specific cancer tissues .

What are the key considerations when using SOCS6 antibodies for immunohistochemistry?

When using SOCS6 antibodies for immunohistochemistry (IHC), researchers should consider several technical factors:

When interpreting IHC results, consider that SOCS6 cellular localization may include cytosol, plasma membrane, and other cytoplasmic locations . Positive and negative control tissues should be included in each experiment to validate staining specificity.

For cancer research applications, compare SOCS6 expression between tumor and adjacent normal tissues, as loss of SOCS6 expression has been associated with certain cancers .

How can SOCS6 antibodies contribute to understanding T cell receptor signaling dynamics?

SOCS6 antibodies enable sophisticated analyses of TCR signaling dynamics through multiple experimental approaches:

• Temporal profiling of signaling regulation:

  • Track SOCS6 expression and localization at precise timepoints after TCR stimulation

  • Monitor correlation between SOCS6 recruitment and p56lck degradation

  • Assess the kinetics of negative regulation in the TCR signaling cascade

• Spatial organization analysis:

  • Visualize SOCS6 recruitment to the immunological synapse using confocal microscopy

  • Measure co-localization coefficients between SOCS6 and active p56lck

  • Map SOCS6 distribution within signaling microclusters using super-resolution microscopy

• Signaling pathway interrogation:

  • Identify signaling components affected by SOCS6-mediated regulation

  • Determine how SOCS6 influences downstream events like IL-2 promoter activation

  • Investigate how SOCS6 interacts with other negative regulators of T cell signaling

• Single-cell analysis:

  • Assess cell-to-cell variability in SOCS6 expression and function

  • Correlate SOCS6 levels with T cell activation status at the single-cell level

  • Track dynamic changes in individual cells during immune response development

Research has shown that SOCS6 binding to active p56lck is detected 1-2 hours after TCR stimulation, with maximum binding at 60-120 minutes, providing important timing guidelines for experimental design .

What approaches can be used to study SOCS6's role in cancer biology?

SOCS6 antibodies facilitate multiple approaches to investigating SOCS6's role in cancer:

• Expression profiling:

  • Quantify SOCS6 protein levels across different cancer types using tissue microarrays

  • Compare SOCS6 expression between primary tumors and metastatic lesions

  • Correlate expression with clinical parameters and patient outcomes

• Functional analysis:

  • Examine how SOCS6 loss affects proliferation, migration, and invasion in cancer models

  • Investigate SOCS6-dependent regulation of oncogenic signaling pathways

  • Study how SOCS6 deficiency impacts mitochondrial dynamics and apoptosis resistance

• Mechanistic investigation:

  • Identify cancer-specific interaction partners of SOCS6

  • Determine how SOCS6 loss contributes to dysregulated cellular signaling

  • Assess potential synthetic lethality approaches in SOCS6-deficient cancers

• Therapeutic implications:

  • Screen for compounds that restore SOCS6 expression or function

  • Develop biomarkers based on SOCS6 status for treatment stratification

  • Monitor SOCS6 levels as indicators of treatment response

Research has demonstrated that biallelic inactivation of the SOCS6 gene is a frequent event in human gastric cancer, with SOCS6 depletion linked to suppression of programmed cell death . SOCS6 antibodies have been validated for IHC applications in human mammary cancer, liver cancer, and lung cancer samples .

How can researchers optimize protocols for detecting SOCS6 in the immunological synapse?

Visualization of SOCS6 at the immunological synapse requires specialized protocols:

• Conjugate formation:

  • For APC-T cell conjugation, use Staphylococcus enterotoxin E (SEE) or anti-CD3/CD28 stimulation

  • Allow sufficient time for synapse formation (typically 15-30 minutes)

  • Fix cells at different timepoints to capture dynamic recruitment

• Immunofluorescence protocol optimization:

  • Gentle fixation (4% paraformaldehyde) to preserve membrane structures

  • Careful permeabilization to maintain synapse architecture

  • Use high-sensitivity detection systems for possibly low-abundance SOCS6

• Co-staining strategy:

  • Co-stain with markers of the immunological synapse (CD3, LFA-1)

  • Use phospho-specific antibodies against active p56lck (phospho-Src Tyr-417)

  • Include markers for specific synapse domains (central SMAC vs. peripheral SMAC)

• Advanced imaging techniques:

  • Implement confocal microscopy with z-stack acquisition

  • Consider super-resolution approaches for detailed localization

  • Use quantitative image analysis to measure SOCS6 enrichment at the synapse

Research has shown that upon APC-T cell conjugation, SOCS6 is recruited to the immunological synapse and colocalizes with the active form of p56lck . This localization is functionally significant as it positions SOCS6 to regulate TCR signaling through targeted degradation of active p56lck.

What are the emerging applications for SOCS6 antibodies in research?

SOCS6 antibodies are poised to contribute to several emerging research areas:

• Single-cell protein analysis:

  • Integration with mass cytometry for high-dimensional analysis of SOCS6 in immune cell subsets

  • Correlation of SOCS6 expression with activation states in heterogeneous populations

  • Development of antibody-based biosensors for real-time monitoring of SOCS6 activity

• Therapeutic development:

  • Screening platforms to identify modulators of SOCS6 expression or function

  • Biomarker development for personalized treatment approaches

  • Therapeutic antibodies targeting pathways regulated by SOCS6

• Systems biology approaches:

  • Antibody-based proteomics to map SOCS6 interaction networks under different conditions

  • Integration of SOCS6 into signaling circuit models of T cell activation

  • Multi-omics correlations between SOCS6 protein levels and transcriptomic/metabolomic profiles

• Translational applications:

  • Clinical correlation studies of SOCS6 expression in patient samples

  • Development of diagnostic approaches based on SOCS6 status

  • Prognostic indicators based on SOCS6 expression patterns in disease states

The continued refinement of SOCS6 antibodies with improved specificity, sensitivity, and application versatility will be crucial for advancing these emerging research directions.

How can researchers address common challenges when working with SOCS6 antibodies?

Several strategies can help overcome common challenges with SOCS6 antibodies:

When investigating SOCS6-dependent protein degradation, the inclusion of proteasome inhibitors like LLnL or epoxomicin is essential, as demonstrated in studies of SOCS6-p56lck interactions .

For cancer-related studies, consider that SOCS6 expression may be significantly reduced or absent in certain tumors, necessitating careful assay sensitivity optimization and appropriate positive controls .